ImageneBio, Inc.

About ImageneBio, Inc.

Imagene Bio is pioneering a new generation of therapies with best-in-class potential for immunological and inflammatory diseases. They leverage external innovation and their proprietary QuadraTek® platform to develop differentiated treatments aimed at offering better outcomes for patients.

Products & Services

Lead Candidates:Engineered to address a broad spectrum of immune and inflammatory indications while optimizing safety, efficacy, and convenience.

Therapies for Immunologic and Inflammatory Diseases:Developing a new generation of therapies for patients with these conditions.

Specialties

Immunological Diseases Inflammatory Diseases Anti-OX40/OX40L Monoclonal Antibodies QuadraTek® Platform

Funding History

Debug: View Raw Funding Data

#	Type	Amount Fields	Date Fields	Investors
1	RT: Private Placement T: - FT: Private Placement	A: 30000000 MR: - FA: approximately $30 million FAN: 30000000	D: 2026-04-13 FD: 2026-04-13	4 investors

Private Placement Latest

2026-04-13

$30.0M

4 investors (Pro only)

Growth Metrics

+45%

Employee Growth

YoY

3.2x

Funding Growth

Last Round

12

Markets

Operating

10K+

Customers

Active

View 3 more growth metrics with Pro

Unlock All Metrics

Mock Up

Team & Leadership

K

Kristin Yarema

Chief Executive Officer and Director

Y

Yufang Lu

Chief Medical Officer

J

Jotin Marango

Chief Financial Officer

A

Anna Vardanyan

Senior Vice President of Corporate and Business Development

E

Erin Butler

Senior Vice President of Finance and Administration

D

David P. Bonita

Board Member

View 7 more team members with Pro

Unlock Full Team Directory

Recent News

ImageneBio, Inc. Announces New Product Launch

2 days ago

Company unveils innovative solution to transform the industry, expanding market reach and capabilities...

Leadership Team Expands with Industry Veteran

1 week ago

New executive brings 20+ years of experience to accelerate growth and strategic initiatives...

Company Recognized as Industry Leader

2 weeks ago

Receives prestigious award for innovation and customer satisfaction in competitive market...

Key Competitors

C1

Competitor Alpha

Series B · $50M raised

C2

Competitor Beta

Series C · $120M raised

C3

Competitor Gamma

Series A · $25M raised

C4

Competitor Delta

Seed · $10M raised